AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01546493 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: qCT
Description: Quantitative computed tomography(QCT) scans using a CT phantom
Study NCT01546493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion Analysis
Description: 3D motion analysis to assess hip function.
Study NCT01546493 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: Positron emission tomography combined with magnetic resonance imaging (PET-MRI) is a technology that will help us examine bone and cartilage at the molecular level.
Study NCT02395354 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Placing a self-expanding metallic stent
Description: * Income on short stay unit (SSU) post-procedure~* Light sedation by the endoscopist vs anesthetist by center~* Fully covered self-expanding metal stents Tae Woong Medical® type; prosthesis size at the endoscopist discretion~* Clips can be placed at the distal end of the prosthesis according to the endoscopist.~* Prosthesis removal time in 4 weeks.
Study NCT02395354 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: A balloon dilatation
Description: * Income on short stay unit (SSU) post-procedure~* Light sedation by the endoscopist vs anesthetist by center.~* Pneumatic ball type CRE Boston cientific®; balloon diameter at the endoscopist discretion~* Up to 2 expansion will be made with a minimum interval between 15-30 days between each expansion~* It shall be deemed failure to expansion if required> 2 expansions.
Study NCT04071951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist-led Hospital Discharge Care Intervention
Description: Pharmacists will address medication reconciliation, medication adherence, and polypharmacy issues as appropriate. Pharmacists will rely most on their prior training, but study investigators will also encourage the use of documentation templates with reminders, Beers list, deprescribing, motivational interviewing, the Medication Adherence and Literacy tool, and post-discharge phone calls.~Pharmacists will assess patient needs and customize accordingly. All patients will receive one discharge counseling visit and one post-discharge phone call, but pharmacists will find that some patients need further phone calls, interventions, referrals, or other interactions. Some or all of the pharmacist activities may take place over the phone.
Study NCT03735420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanthohumol
Description: The xanthohumol supplement will be administered in a capsule. Participants in the experimental arm will consume the capsule once per day, with the first meal. The intervention will extend for 8 weeks.
Study NCT03735420 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The placebo (vehicle) will be administered in a capsule. Participants in the placebo arm will consume the capsule once per day, with the first meal.
Study NCT02444741 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo PBRT
Study NCT04456699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 300 mg BID, oral until progressive disease or end of study
Study NCT04456699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 2400 mg/m\^2 over 46 to 48 hours Q2W IV infusion until disease progression or end of study; bolus 5-FU (400mg/m2) can be added prior to infusional 5-FU, per local standards and at the investigator's discretion
Study NCT04456699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg or 7.5 mg/kg Q2W or Q3W IV infusion until progressive disease or end of study
Study NCT04456699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg or 7.5 mg/kg Q2W or Q3W IV infusion until progressive disease or end of study
Study NCT04456699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m\^2 oral capsule BID for 14 days, then 7 days off, Q3W) until progressive disease or end of study
Study NCT04456699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin/ levoleucovorin
Description: 400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) may be added to Bevacizumab + 5-FU per investigator's discretion Q2W IV infusion until progressive disease or end of study
Study NCT04079933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral tobacco-derived nicotine product (OTDN)
Study NCT01717573 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deferred stenting
Study NCT01717573 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Study NCT04508803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008，Niraparib
Description: Subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Niraparib orally per day.Every 3 weeks is a cycle.
Study NCT04508803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008，Niraparib，Trastuzumab
Description: Subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day;Trastuzumab 8mg/kg in the first cycle and 6mg/kg after the first cycle intravenously once every 3 weeks; Every 3 weeks is a cycle.
Study NCT04508803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX008，Niraparib，Pyrrolitinib
Description: HER-2 negative subjects received intravenous HX008 at a fixed dose of 200mg, administered every 3 weeks, and 200mg of Neirapali orally per day. Every 3 weeks is a cycle.~Her-2 positive subjects received intravenous HX008 at a fixed dose of 200mg once every 3 weeks; 200mg Niraparib orally per day; Pyrrolitinib is taken orally at 400mg per day; Every 3 weeks is a cycle.
Study NCT03193294 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Stratified medicine involving a diagnostic intervention
Description: Adjunctive tests of coronary artery function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with no-obstructive coronary artery disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results). Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013)).
Study NCT03193294 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Stratified medicine involving a diagnostic intervention
Description: Adjunctive tests of coronary artery function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with no-obstructive coronary artery disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results). Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013)).
Study NCT04040972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compassion Focussed Therapy
Description: Group compassion focussed therapy. One session every week for 10 weeks. Each session lasts 2.5 hours with two breaks during this time.
Study NCT03588169 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: semi-structured interviews
Description: About 30 minutes and touching on the following subjects:~* perception of hospital meals~* patient representation of ONS~* taking ONS and feelings about it
Study NCT03731494 — intervention group
Intervention type: BIOLOGICAL
Intervention: Nickel oral hyposensitization treatment
Description: Nickel oral hyposensitization treatment (NiOHT) was performed with hard gelatin capsules containing Nickel sulphate (NiSO4) at different dosages (0.1 ng, 1 ng, 10 ng, 0.1 μg, 0.5 μg) and microcrystalline cellulose as excipient (TIO Nickel, Lofarma SpA, Milan, Italy). Treatment was given 3 times a week increasing progressively the dose from 0.1 ng to 3 μg in 10 weeks with a maintenance phase of 1,5 μg a week for a period of 12 months. After 6 months, patients were allowed to gradually reintroduce nickel-rich foods, starting with those with a maximum of 100 mcg of nickel content. For all the treatment period, information on the appearance of side effects or more severe adverse reactions and the need for antiallergic drugs (corticosteroids, antihistamine drugs) were collected.
Study NCT01025700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cesemat
Description: 1 mg capsule per day for 21 days
Study NCT03030612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-110
Description: ARGX-110 will be administered intravenously.
Study NCT03030612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZA
Description: AZA will be administered subcutaneously/intravenously.
Study NCT05350293 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Molded abutment
Description: The waxed plastic abutment will dismantle, wedged, and poured using a Ni-Cr mixture then it will be trimmed to make it ready to make the permanent restoration over it.~The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner.
Study NCT05350293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed abutment
Description: A marker or Scan body appropriate for the type of implant will be placed on the laboratory implant substitute, a digital scan of the marker will be done in the lab, and the scanned image will be transferred to a computer design software where the prosthesis is designed, In the printing phase, the final prosthesis will be manufactured using a stepwise metal powder supply and a laser fusion process. Making the abutment ready to make the permanent restoration over it. The prostheses will be cemented above the abutment using dual-cure resin cement then the final restoration (crown and abutment) will be fixed using a screw-retained manner.
Study NCT02774109 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Five 1000mg fish oil soft capsules per day (each capsule containing 350mg EPA and 250mg DHA) for 8 weeks
Study NCT02774109 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Five 1000mg sunflower oil soft capsules per day for 8 weeks
Study NCT02774109 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hotpacking
Description: Hotpacking 15min on low back, three times a week for 8 weeks
Study NCT02774109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hotpacking
Description: Hotpacking 15min on low back, three times a week for 8 weeks
Study NCT02774109 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Transcutaneous electrical nerve stimulation (TENS) 15min on low back, three times a week for 8 weeks
Study NCT02774109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Transcutaneous electrical nerve stimulation (TENS) 15min on low back, three times a week for 8 weeks
Study NCT02444741 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo low dose radiation therapy
Study NCT01169324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alteration of DBS stimulator settings
Description: Alteration of DBS stimulator settings
Study NCT01827904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial ExAblate
Study NCT01827904 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial ExAblate
Study NCT01769794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Western therapy
Description: Physical cooling paste or warm bathing, vitamin B, vitamin C. On the basis of the attending physician's judgment, participants were allowed to use Ibuprofen suspension if their body temperature was greater than 38.5℃. Likewise, the need for antibiotics was determined by the attending physicians. The use of acetaminophen or antibiotics was recorded on the case record form
Study NCT01769794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Western therapy
Description: Physical cooling paste or warm bathing, vitamin B, vitamin C. On the basis of the attending physician's judgment, participants were allowed to use Ibuprofen suspension if their body temperature was greater than 38.5℃. Likewise, the need for antibiotics was determined by the attending physicians. The use of acetaminophen or antibiotics was recorded on the case record form
Study NCT01769794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JET
Description: 4g/tablet, One tablet each time (Taken after dissolved in 50ml boiled water, 3 times daily if body temperature≥38.5℃)
Study NCT01769794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo(for JET)
Description: placebos prepared identical in color, taste and consistency to the JET (supplied by Zhongshenghaitian Pharmaceutical, Tianjin, China)
Study NCT02444741 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT02297724 — intervention group
Intervention type: OTHER
Intervention: Oxygen
Description: Administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan.
Study NCT03466788 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self questionnaires of quality of life and living conditions
Description: Patients will complete self-questionnaires of living conditions and quality of life (QLQ-C30; EN24; CIPN20; IPAQ; HADS)
Study NCT00716027 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard behavioral treatment for weight loss
Description: A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity.
Study NCT00716027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified behavioral treatment for weight loss
Description: A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity. In this intervention, individuals not meeting weight loss goals will be given one-on-one treatment.
Study NCT02181842 — intervention group
Intervention type: DRUG
Intervention: Pioglitazone
Description: Pioglitazone tablets
Study NCT01261962 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc
Description: zinc sulfate, 35 mg twice daily for 4 months
Study NCT01261962 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: zinc
Description: zinc sulfate, 35 mg twice daily for 4 months
Study NCT01261962 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, One capsule, twice daily for 4 months
Study NCT01261962 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo, One capsule, twice daily for 4 months
Study NCT02773641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Study NCT02773641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline Solution
Study NCT00819091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1356
Description: 5mg orally (po) tablet qd
Study NCT00819091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 1356 5mg one tablet daily
Study NCT04160416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine-Oxaliplatin-Irinotecan Combination
Description: CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; CET: 500 mg/sq.m (d.i.v.) D1; Administered every 2 weeks.
Study NCT01432600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.
Study NCT01432600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.
Study NCT01835782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Serine
Study NCT02067403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure-support Eadi optimization
Study NCT01337245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Snake (Micrurus) North American immune F(ab')2 Equine
Description: 5 vials of study drug reconstituted and diluted to 250 mL Normal Saline and administered intravenously.
Study NCT01432600 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pomalidomide
Description: Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.
Study NCT01432600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.
Study NCT01432600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.
Study NCT01432600 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.
Study NCT01432600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The dose escalation uses a standard 3x3 design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study.
Study NCT01432600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: The dose escalation uses a standard 3x3 design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study.
Study NCT01432600 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: The dose escalation uses a standard 3x3 design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study.
Study NCT02851394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Study NCT02851394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levobupivacaine
Study NCT04637217 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography
Description: Spectral Domain Optical Coherence Tomography(SD-OCT) examination will be performed for every patient: posterior pole scan, EDI-OCT(enhanced depth imaging-OCT) and peripapillary RNFL(retinal nerve fiber layer)
Study NCT03494010 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: There is no intervention. Patients will receive the HCL system as part of their clinical care.
Study NCT00228449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Study NCT00562848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040
Description: GSK962040 will be supplied in the following tablet strengths: 1 milligram, 5m milligrams, 25 milligrams, 125 milligrams.
Study NCT03495700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L-PRF block
Description: The use of the L-PRF block as graft material for sinus augmentation procedure will be analysed
Study NCT03495700 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DBBM
Description: The use of bovine xenograft will be analysed
Study NCT00698607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (Xience or Promus)
Description: Use everolimus-eluting stent in the treatment of coronary stenosis
Study NCT00698607 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-eluting stent (Cypher)
Description: Use sirolimus-eluting stent in the treatment of coronary stenosis
Study NCT00698607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-month clopidogrel therapy
Description: Use clopidogrel for 6 months
Study NCT00698607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6-month clopidogrel therapy
Description: Use clopidogrel for 6 months
Study NCT00698607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12-month clopidogrel therapy
Description: Use clopidogrel for 12 months